D J Birkett

Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.

J. Miners, J O Miners, D J Birkett, 1998, British journal of clinical pharmacology.

Variability of L-dopa absorption in man.

D J Birkett, D N Wade, P T Mearrick, 1974, Australian and New Zealand journal of medicine.

The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism.

G. Shenfield, J. Miners, J. Goldstein, 1996, Pharmacogenetics.

Tolbutamide hydroxylation by human liver microsomes. Kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations.

J. Miners, R. Robson, M. McManus, 1988, Biochemical pharmacology.

The characterization of two specific drug binding sites on human serum albumin.

G. Sudlow, D J Birkett, D N Wade, 1975, Molecular pharmacology.

Cytochromes P450, 1A2, and 2C9 are responsible for the human hepatic O-demethylation of R- and S-naproxen.

R. Tukey, J. Miners, J O Miners, 1996, Biochemical pharmacology.

The xenobiotic inhibitor profile of cytochrome P4502C8.

J. Miners, J O Miners, D J Birkett, 2000, British journal of clinical pharmacology.

Further characterization of specific drug binding sites on human serum albumin.

G. Sudlow, D J Birkett, D N Wade, 1976, Molecular pharmacology.